Almirall
Almirall is a Barcelona dermatology company whose cancer-related product is tirbanibulin ointment for actinic keratosis, approved in the United States in 2020 and in Europe in 2021.
Overview
Almirall, listed on the Spanish stock exchange, is a pharmaceutical company focused on medical dermatology. Its contribution to cancer prevention is tirbanibulin (Klisyri), a topical microtubule inhibitor for actinic keratosis of the face and scalp, the precancerous lesion that can progress to squamous cell skin cancer, approved by the FDA in December 2020 and the European Commission in 2021. OnCo records it so that its phase 3 trials resolve to a sponsor page.
Similar pages
not linked directly; found by shared links- CompanyLEO Pharma
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyGalderma
Shares Cutaneous squamous cell carcinoma and the tag ctgov-sponsor.